Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer

Authors: Biao Fan, Lian-Hai Zhang, Yong-ning Jia, Xi-Yao Zhong, Yi-Qiang Liu, Xiao-Jing Cheng, Xiao-Hong Wang, Xiao-Fang Xing, Ying Hu, Ying-Ai Li, Hong Du, Wei Zhao, Zhao-Jian Niu, Ai-Ping Lu, Ji-You Li, Jia-Fu Ji

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

S100A9 was originally discovered as a factor secreted by inflammatory cells. Recently, S100A9 was found to be associated with several human malignancies. The purpose of this study is to investigate S100A9 expression in gastric cancer and explore its role in cancer progression.

Methods

S100A9 expression in gastric tissue samples from 177 gastric cancer patients was assessed by immunohistochemistry. The expression of its dimerization partner S100A8 and the S100A8/A9 heterodimer were also assessed by the same method. The effect of exogenous S100A9 on motility of gastric cancer cells AGS and BGC-823 was then investigated.

Results

S100A9 was specifically expressed by inflammatory cells such as macrophages and neutrophils in human gastric cancer and gastritis tissues. Statistical analysis showed that a high S100A9 cell count (> = 200) per 200x magnification microscopic field in cancer tissues was predictive of early stage gastric cancer. High S100A9-positive cell count was negatively correlated with lymph node metastasis (P = 0.009) and tumor invasion (P = 0.011). S100A9 was identified as an independent prognostic predictor of overall survival of patients with gastric cancer (P = 0.04). Patients with high S100A9 cell count were with favorable prognosis (P = 0.021). Further investigation found that S100A8 distribution in human gastric cancer tissues was similar to S100A9. However, the number of S100A8-positive cells did not positively correlate with patient survival. The inflammatory cells infiltrating cancer were S100A8/A9 negative, while those in gastritis were positive. Furthermore, exogenous S100A9 protein inhibited migration and invasion of gastric cancer cells.

Conclusions

Our results suggested S100A9-positive inflammatory cells in gastric cancer tissues are associated with early stage of gastric cancer and good prognosis.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Karpeh MS, Leon L, Klimstra D, Brennan MF: Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000, 232 (3): 362-371. 10.1097/00000658-200009000-00008.CrossRefPubMedPubMedCentral
3.
Smith DD, Schwarz RR, Schwarz RE: Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005, 23 (28): 7114-7124. 10.1200/JCO.2005.14.621.CrossRefPubMed
4.
Fatourou E, Ziogas D, Baltogiannis G: Moving from lymph node metastasis in gastric cancer to biological markers. World J Surg. 2010, 34 (5): 1140-1141. 10.1007/s00268-009-0368-9.CrossRefPubMed
5.
Roukos DH: Genome-wide association studies: how predictable is a person's cancer risk?. Expert Rev Anticancer Ther. 2009, 9 (4): 389-392. 10.1586/era.09.12.CrossRefPubMed
6.
Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005, 5 (11): 845-856. 10.1038/nrc1739.CrossRefPubMed
7.
Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008, 34 (4): 357-364. 10.1016/j.ejso.2007.04.009.CrossRefPubMed
8.
Leukert N, Sorg C, Roth J: Molecular basis of the complex formation between the two calcium-binding proteins S100A8 (MRP8) and S100A9 (MRP14). Biol Chem. 2005, 386 (5): 429-434.CrossRefPubMed
9.
Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J: Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol. 2006, 359 (4): 961-972. 10.1016/j.jmb.2006.04.009.CrossRefPubMed
10.
Halayko AJ, Ghavami S: S100A8/A9: a mediator of severe asthma pathogenesis and morbidity?. Can J Physiol Pharmacol. 2009, 87 (10): 743-755. 10.1139/Y09-054.CrossRefPubMed
11.
Foell D, Wittkowski H, Roth J: Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009, 58 (6): 859-868. 10.1136/gut.2008.170019.CrossRefPubMed
12.
Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS: Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007, 42 (11): 1321-1331. 10.1080/00365520701416709.CrossRefPubMed
13.
Goebeler M, Roth J, Burwinkel F, Vollmer E, Bocker W, Sorg C: Expression and complex formation of S100-like proteins MRP8 and MRP14 by macrophages during renal allograft rejection. Transplantation. 1994, 58 (3): 355-361.CrossRefPubMed
14.
Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H: Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994, 35 (5): 669-674. 10.1136/gut.35.5.669.CrossRefPubMedPubMedCentral
15.
Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006, 72 (11): 1622-1631. 10.1016/j.bcp.2006.05.017.CrossRefPubMed
16.
Kawai H, Minamiya Y, Takahashi N: Prognostic impact of S100A9 over expression in non-small cell lung cancer. Tumour Biol. 2011, 32 (4): 641-646. 10.1007/s13277-011-0163-8.CrossRefPubMed
17.
Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005, 11 (14): 5146-5152. 10.1158/1078-0432.CCR-05-0352.CrossRefPubMed
18.
Cross SS, Hamdy FC, Deloulme JC, Rehman I: Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005, 46 (3): 256-269. 10.1111/j.1365-2559.2005.02097.x.CrossRefPubMed
19.
Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R: S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008, 8 (4): 243-252. 10.2174/156800908784533445.CrossRefPubMed
20.
Wang J, Cai Y, Xu H, Zhao J, Xu X, Han YL, Xu ZX, Chen BS, Hu H, Wu M, et al: Expression of MRP14 gene is frequently down-regulated in Chinese human esophageal cancer. Cell Res. 2004, 14 (1): 46-53. 10.1038/sj.cr.7290201.CrossRefPubMed
21.
Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I, Khattak I, et al: Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis. 2010, 31 (9): 1541-1551. 10.1093/carcin/bgq137.CrossRefPubMed
22.
Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG: Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum. 2008, 51 (11): 1703-1709. 10.1007/s10350-008-9381-6.CrossRefPubMed
23.
El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF, Powell SM: Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002, 62 (23): 6823-6826.PubMed
24.
Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, et al: Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010, 9 (8): 4123-4130. 10.1021/pr100302b.CrossRefPubMedPubMedCentral
25.
Ji J, Chen X, Leung SY, Chi JT, Chu KM, Yuen ST, Li R, Chan AS, Li J, Dunphy N, et al: Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene. 2002, 21 (42): 6549-6556. 10.1038/sj.onc.1205829.CrossRefPubMed
26.
Zhang YZ, Zhang LH, Gao Y, Li CH, Jia SQ, Liu N, Cheng F, Niu DY, Cho WC, Ji JF, et al: Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol. 2011, 17 (13): 1710-1717. 10.3748/wjg.v17.i13.1710.CrossRefPubMedPubMedCentral
27.
de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6 (1): 24-37. 10.1038/nrc1782.CrossRefPubMed
28.
29.
Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac-Jurcevic T, et al: The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics. 2007, 7 (11): 1929-1940. 10.1002/pmic.200700072.CrossRefPubMed
30.
Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R: S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer. 2004, 40 (8): 1179-1187. 10.1016/j.ejca.2004.01.022.CrossRefPubMed
31.
Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007, 81 (1): 28-37.CrossRefPubMed
32.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, et al: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007, 13 (9): 1042-1049. 10.1038/nm1638.CrossRefPubMed
33.
34.
Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T, et al: S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Res. 2009, 29 (10): 4157-4161.PubMed
35.
Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L: The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 2007, 22 (9): 1025-1032.PubMed
36.
Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C: S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 2009, 625 (1–3): 73-83.CrossRefPubMed
37.
Yui S, Nakatani Y, Mikami M: Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003, 26 (6): 753-760. 10.1248/bpb.26.753.CrossRefPubMed
38.
Luley K, Noack F, Lehnert H, Homann N: Local calprotectin production in colorectal cancer and polyps–active neutrophil recruitment in carcinogenesis. Int J Colorectal Dis. 2011, 26 (5): 603-607. 10.1007/s00384-011-1165-0.CrossRefPubMed
39.
Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007, 117 (5): 1175-1183. 10.1172/JCI31537.CrossRefPubMedPubMedCentral
40.
Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006, 90: 1-50.CrossRefPubMed
41.
Bui JD, Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol. 2007, 19 (2): 203-208. 10.1016/j.coi.2007.02.001.CrossRefPubMed
42.
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ: Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A. 2008, 105 (2): 652-656. 10.1073/pnas.0708594105.CrossRefPubMedPubMedCentral
Metadata
Title
Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer
Authors
Biao Fan
Lian-Hai Zhang
Yong-ning Jia
Xi-Yao Zhong
Yi-Qiang Liu
Xiao-Jing Cheng
Xiao-Hong Wang
Xiao-Fang Xing
Ying Hu
Ying-Ai Li
Hong Du
Wei Zhao
Zhao-Jian Niu
Ai-Ping Lu
Ji-You Li
Jia-Fu Ji
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-316

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

RON is not a prognostic marker for resectable pancreatic cancer

Research article

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

Research article

External validation of the Bayesian Estimated Tools for Survival (BETS) models in patients with surgically treated skeletal metastases

Case report

Axillary node metastasis from differentiated thyroid carcinoma with hürthle and signet ring cell differentiation. A case of disseminated thyroid cancer with peculiar histologic findings

Research article

Necdin modulates proliferative cell survival of human cells in response to radiation-induced genotoxic stress

Research article

Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits